City

Corona (1)

Duarte (1)

Houston (1)

Lancaster (1)

Mission Hills (1)

Providence (1)

Rancho Cucamonga (1)

South Pasadena (1)

West Covina (1)

Overall Status

Active, not recruiting (1)

Not yet recruiting (1)

Recruiting (1)

Phase

phase 1 (2)

phase 2 (1)

Sponsor

Brown University (1)

City of Hope Medical Center (1)

M.D. Anderson Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (2)

Cures Within Reach (1)

Legorreta Cancer Center at Brown University (1)

Lifespan (1)

Intervention

alpelisib (1)

degarelix (1)

enobosarm (1)

enzalutamide (1)

gemcitabine/cisplatin (1)

laboratory biomarker analysis (1)

pembrolizumab (1)

Study Documents

Intervention Type

drug (3)

biological (1)

combination product (1)

other (1)

Funder Type

Other (3)

Study Type

Interventional (3)

androgen receptor positive

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting

Urothelial Carcinoma Bladder
Androgen Receptor Positive

Degarelix
Gemcitabine/Cisplatin

Providence, Rhode Island

Lifespan Cancer Institute

May 1, 2023

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting

Advanced Breast Carcinoma
+17 more

Houston, Texas

M D Anderson Cancer Center

Dec 5, 2022

Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)

Active, not recruiting

Has Results

Androgen Receptor Positive
+5 more

Enobosarm
+2 more

Corona, California
+6 more

Jun 8, 2022